NCT04445246View on ClinicalTrials.gov

Inhaled Iloprost for Suspected COVID-19 Respiratory Failure

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 23, 2020

Primary Completion Date

May 31, 2021

Study Completion Date

May 31, 2021

Conditions
COVID-19ARDS, HumanHypoxemic Respiratory Failure
Interventions
DRUG

Inhaled ILOPROST

Inhaled Iloprost 20 mcg every 8 hours for 5 days only delivered by nebulization.

Trial Locations (1)

Unknown

Hamad Medical Corporation, Doha

Sponsors
All Listed Sponsors
lead

Hamad Medical Corporation

INDUSTRY